Opko Health (OPK) Upgraded at BidaskClub

Opko Health (NASDAQ:OPK) was upgraded by stock analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a report issued on Friday.

Several other equities research analysts have also issued reports on the company. Zacks Investment Research lowered Opko Health from a “hold” rating to a “sell” rating in a report on Wednesday. Cantor Fitzgerald set a $20.00 price target on Opko Health and gave the company a “buy” rating in a report on Wednesday, October 25th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the stock. Opko Health currently has a consensus rating of “Hold” and an average price target of $13.34.

Shares of Opko Health (NASDAQ:OPK) traded down $0.12 during midday trading on Friday, reaching $4.88. The company’s stock had a trading volume of 3,738,576 shares, compared to its average volume of 4,300,000. Opko Health has a 12-month low of $4.28 and a 12-month high of $8.92. The firm has a market cap of $2,660.00, a price-to-earnings ratio of -25.68 and a beta of 1.82. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.66 and a quick ratio of 1.48.

Opko Health (NASDAQ:OPK) last announced its quarterly earnings results on Wednesday, November 8th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.05) by ($0.03). The firm had revenue of $263.50 million for the quarter, compared to analyst estimates of $319.43 million. Opko Health had a negative net margin of 9.45% and a negative return on equity of 5.17%. The firm’s quarterly revenue was down 11.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.03) earnings per share. equities research analysts forecast that Opko Health will post -0.27 EPS for the current fiscal year.

In other Opko Health news, major shareholder Opko Health, Inc. purchased 655,738 shares of the company’s stock in a transaction on Monday, October 30th. The shares were bought at an average cost of $3.05 per share, with a total value of $2,000,000.90. Following the transaction, the insider now directly owns 6,678,752 shares in the company, valued at approximately $20,370,193.60. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Phillip Md Et Al Frost purchased 100,000 shares of the company’s stock in a transaction on Monday, January 22nd. The stock was acquired at an average cost of $4.40 per share, for a total transaction of $440,000.00. Following the completion of the transaction, the chief executive officer now owns 3,068,951 shares in the company, valued at $13,503,384.40. The disclosure for this purchase can be found here. Insiders purchased a total of 855,738 shares of company stock worth $2,929,001 over the last three months. 40.19% of the stock is owned by company insiders.

Hedge funds and other institutional investors have recently modified their holdings of the business. Crossmark Global Holdings Inc. bought a new position in Opko Health in the 3rd quarter worth approximately $118,000. The Manufacturers Life Insurance Company increased its position in Opko Health by 7.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,535 shares of the biotechnology company’s stock worth $149,000 after buying an additional 1,657 shares during the period. Psagot Investment House Ltd. increased its position in Opko Health by 20.0% in the 2nd quarter. Psagot Investment House Ltd. now owns 22,862 shares of the biotechnology company’s stock worth $150,000 after buying an additional 3,806 shares during the period. Prudential Financial Inc. increased its position in Opko Health by 6.1% in the 2nd quarter. Prudential Financial Inc. now owns 24,511 shares of the biotechnology company’s stock worth $161,000 after buying an additional 1,400 shares during the period. Finally, State of Alaska Department of Revenue bought a new position in Opko Health in the 4th quarter worth approximately $144,000. 22.88% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “Opko Health (OPK) Upgraded at BidaskClub” was reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another site, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this article can be accessed at https://www.americanbankingnews.com/2018/01/27/opko-health-opk-upgraded-at-bidaskclub.html.

Opko Health Company Profile

OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.

Analyst Recommendations for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply